S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PRTA

Prothena (PRTA) Stock Price, News & Analysis

$24.77
-0.39 (-1.55%)
(As of 03/28/2024 ET)
Today's Range
$24.29
$25.34
50-Day Range
$24.75
$34.07
52-Week Range
$24.25
$79.65
Volume
803,163 shs
Average Volume
578,651 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.63

Prothena MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
181.1% Upside
$69.63 Price Target
Short Interest
Bearish
11.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.45mentions of Prothena in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$170,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.87) to ($4.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.43 out of 5 stars

Medical Sector

308th out of 938 stocks

Pharmaceutical Preparations Industry

133rd out of 417 stocks

PRTA stock logo

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

PRTA Stock News Headlines

Demystifying Prothena Corp: Insights From 8 Analyst Reviews
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Prothena Corporation plc (PRTA)
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
PRTA Mar 2024 105.000 call
Prothena Full Year 2023 Earnings: Beats Expectations
RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)
Decoding 6 Analyst Evaluations For Prothena Corp
Earnings Outlook For Prothena Corp
Navigating 5 Analyst Ratings For Prothena Corp
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTA
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$69.63
High Stock Price Target
$90.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+181.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-147,030,000.00
Net Margins
-160.91%
Pretax Margin
-175.64%

Debt

Sales & Book Value

Annual Sales
$91.37 million
Book Value
$10.46 per share

Miscellaneous

Free Float
38,571,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
0.22
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price target for 2024?

9 brokers have issued 12 month price objectives for Prothena's stock. Their PRTA share price targets range from $35.00 to $90.00. On average, they anticipate the company's share price to reach $69.63 in the next twelve months. This suggests a possible upside of 181.1% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2024?

Prothena's stock was trading at $36.34 on January 1st, 2024. Since then, PRTA stock has decreased by 31.8% and is now trading at $24.77.
View the best growth stocks for 2024 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) issued its quarterly earnings data on Thursday, February, 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by $0.03. The biotechnology company earned $0.32 million during the quarter, compared to the consensus estimate of $2.15 million. Prothena had a negative trailing twelve-month return on equity of 24.84% and a negative net margin of 160.91%. The company's revenue was down 99.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.12 earnings per share.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Who are Prothena's major shareholders?

Prothena's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.90%), Price T Rowe Associates Inc. MD (7.90%), Wellington Management Group LLP (4.83%), Palo Alto Investors LP (3.09%), First Light Asset Management LLC (2.03%) and Vanguard Group Inc. (1.99%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners